Hello,

Thank you for expressing interest in our study. The purpose of this study is to investigate brain function associated with a single dose of psilocybin and an associated course of therapy. 

The study will require approximately 14-18 visits to the Martinos Center in Boston, MA over the course of 5 months. Basic eligibility criteria include being between the ages of 18-55 and passing a neuroimaging safety screen. There are additional criteria that we will review at the time of screening. For a more comprehensive list of eligibility criteria, please refer to our listing on https://clinicaltrials.gov/study/NCT06247839 

Unfortunately, since the study includes 14-18 visits to Boston over the course of five months, we are only recruiting locally (MA, RI, CT, NH).  

If you think you meet the eligibility criteria and you are still interested, please fill out our Pre-Screening Survey on RedCap linked below: https://redcap.link/urhwb478 all information you provide on the study questionnaire through the link will be secure and encrypted  

 Unfortunately, we cannot deviate from the criteria listed, so if you do not meet criteria, please see below. 

Based on the information provided in the RedCap Pre-Screening survey, if you meet initial eligibility, we will schedule a virtual pre-screening session with Dr. Ghaznavi. During this session, she will ask you additional questions and review the study’s goals and consent form.  

If after the first remote pre-screening session you still meet eligibility criteria, an additional in-person screening visit will be scheduled. During this session additional questionnaires will be required as well as vitals and a blood draw will be conducted. 

Once both pre-screening sessions are completed, if you are deemed eligible for the study, we will work with you to schedule the rest of the study visits. 

If you do not qualify for the current study, please check back on our website for future studies and please see resources below. 

Please note that we are not a clinical center and therefore do not provide treatment. Psychedelics and psychedelic-assisted therapy, at present, are not FDA-approved treatments (with the exception of ketamine). Therefore, we are only able to provide psychedelic assisted psychotherapy in the context of research studies.  

Resources: 

1. To explore participating in other studies involving psychedelics, please see https://clinicaltrials.gov and https://psychedelic.support/resources/how-to-join-psychedelic-clinical-trial/. 

2. For ketamine treatment at MGH: (https://www.massgeneral.org/psychiatry/treatments-and-services/ketamine-clinic-for-depression). Please note that, currently, they only provide ketamine infusions and do not offer ketamine-assisted psychotherapy. 

3. If you’re thinking about suicide, are worried about a friend or loved one, or would like emotional support contact the Suicide & Crisis Lifeline 988.  

4. If you’re in need of immediate medical attention, please contact your medical providers or go to your nearest emergency room. 

If you have any questions or concerns, please do not hesitate to reach out.  

Thank you.